For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer ...

While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...

BARCELONA — Adding the immune checkpoint inhibitor durvalumab to standard treatment for muscle-invasive bladder cancer (MIBC) ...

Imfinzi is a human monoclonal antibody that targets the PD-L1 protein, whereas Imjudo focuses on the CTLA-4 protein.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Professors Tom Powles and Peter Schmid recently delivered results from their phase three clinical trials during Sunday's ...

The HIMALAYA study showed that the combination of tremelimumab and durvalumab significantly improved overall survival in ...

Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with ...

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure ...

Positive results from the NIAGARA Phase III trial showed that UK pharma major AstraZeneca’s (LSE: AZN) Imfinzi (durvalumab) ...

Adding perioperative durvalumab (Imfinzi) to neoadjuvant chemotherapy significantly improved survival outcomes in ...